Major pharmaceutical company acquires a genomic therapy startup in 2026

The summit underscores the rapid advancements in genomic therapies, with investors expecting consolidation in the sector. A top pharma firm is likely to acquire a smaller, innovative genomic startup to bolster its pipeline and gain a first-mover advantage in gene-editing treatments.

Implied probability (Yes)

75%